All questionsPharmacology: Vraylar (cariprazine), all indications7 questions · 3 sourcesMechanismHow does Vraylar work (mechanism of action)?“The mechanism of action of VRAYLAR is unknown. The efficacy of VRAYLAR is thought to be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors.1” (opens the source at this quote in a new tab)CopyFlag“May act as an agonist to increase signaling when neurotransmitters are low2” (opens the source at this quote in a new tab)CopyFlag“May act as an antagonist to decrease signaling when neurotransmitters are high2” (opens the source at this quote in a new tab)CopyFlagWhich receptors does Vraylar bind to?“Cariprazine acts as a partial agonist at the dopamine D3 and D2 receptors with high binding affinity (Ki values 0.085 nM, and 0.49 nM (D2L) and 0.69 nM (D2S), respectively) and at the serotonin 5-HT1A receptors (Ki value 2.6 nM). Cariprazine acts as an antagonist at 5-HT2B and 5-HT2A receptors with high and moderate binding affinity (Ki values 0.58 nM and 18.8 nM respectively) as well as it binds to the histamine H1 receptors (Ki value 23.2 nM). Cariprazine shows lower binding affinity to the serotonin 5- HT2C and α1A- adrenergic receptors (Ki values 134 nM and 155 nM, respectively) and has no appreciable affinity for cholinergic muscarinic receptors (IC50>1000 nM).” (opens the source at this quote in a new tab)CopyFlag“VRAYLAR demonstrated up to ~8-fold greater in vitro affinity for dopamine D3 vs D2 receptors1” (opens the source at this quote in a new tab)CopyFlag“The clinical significance of the in vitro data is unknown.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is Vraylar metabolized?“Cariprazine is extensively metabolized by CYP3A4 and, to a lesser extent, by CYP2D6 to DCAR and DDCAR. DCAR is further metabolized into DDCAR by CYP3A4 and CYP2D6. DDCAR is then metabolized by CYP3A4 to a hydroxylated metabolite.” (opens the source at this quote in a new tab)CopyFlag“VRAYLAR activity is thought to be mediated by cariprazine and its two major active metabolites, desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), which are pharmacologically equipotent to cariprazine.” (opens the source at this quote in a new tab)CopyFlagIs Vraylar excreted by the kidneys?“Following administration of 12.5 mg/day cariprazine to patients with schizophrenia for 27 days, about 21% of the daily dose was found in urine, with approximately 1.2% of the daily dose excreted in urine as unchanged cariprazine.” (opens the source at this quote in a new tab)CopyFlag“Cariprazine and its major active metabolites are minimally excreted in urine. Pharmacokinetic analyses indicated no significant relationship between plasma clearance and creatinine clearance” (opens the source at this quote in a new tab)CopyFlagHow long does Vraylar stay in your system (half-life)?“~7-day half-life1” (opens the source at this quote in a new tab)CopyFlag“VRAYLAR plasma concentration decreased by ~50% in approximately 1 week‡” (opens the source at this quote in a new tab)CopyFlag“‡After multiple dose administration of VRAYLAR, mean cariprazine and DCAR concentrations reached steady state at around Week 1 to Week 2 and mean DDCAR concentrations approached steady state around Week 4 to Week 8 in a 12-week study. The half-lives based on time to reach steady state were 2 to 4 days for cariprazine, ~1 to 2 days for DCAR, and approximately 1 to 3 weeks for DDCAR. The time to reach steady state for DDCAR was variable across patients, with some not achieving steady state at the end of the 12-week treatment. After discontinuation of VRAYLAR, mean plasma concentrations of cariprazine and DCAR decreased by ~50% in ~1 day, and mean plasma concentration of DDCAR decreased by ~50% 1 week after the last dose. The decline in plasma concentrations of active drug and metabolites may not be immediately reflected in patients’ clinical symptoms.1” (opens the source at this quote in a new tab)CopyFlag“There was an approximately 90% decline in plasma exposure within 1 week for cariprazine and DCAR, and at about 4 weeks for DDCAR. Following a single dose of 1 mg of cariprazine administration, DDCAR remained detectable 8 weeks post-dose.” (opens the source at this quote in a new tab)CopyFlagHow fast does Vraylar reach peak levels?“~3-6 hours to peak plasma concentration1 after 1 dose of VRAYLAR 1.5 mg/day” (opens the source at this quote in a new tab)CopyFlag“After single dose administration of VRAYLAR, the peak plasma cariprazine concentration occurred in approximately 3-6 hours.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Vraylar?“VRAYLAR capsules are intended for oral administration only. Each hard gelatin capsule contains 0.5, 0.75, 1.5, 3, 4.5, or 6 mg of cariprazine base (equivalent to 0.545 mg, 0.818 mg, 1.635 mg , 3.27 mg, 4.905 mg, or 6.54 mg cariprazine HCl). In addition, capsules include the following inactive ingredients: gelatin, magnesium stearate, pregelatinized starch, shellac, and titanium dioxide. Colorants include black iron oxide (0.5, 0.75, 1.5, 3, and 6 mg), FD&C Blue 1 (0.5, 0.75, 3, 4.5, and 6 mg), FD&C Red 3 (6 mg), FD&C Red 40 (3 and 4.5 mg), or yellow iron oxide (0.5, 3, and 4.5 mg).” (opens the source at this quote in a new tab)CopyFlag